Results of One-Year Follow-Up Examinations after Intravitreal Bevacizumab Administration for Chronic Central Serous Chorioretinopathy

Background: Our purpose was to report the results of 1-year follow-up examinations after intravitreal bevacizumab injection for the treatment of chronic central serous chorioretinopathy (CSC). Methods: Five eyes in 5 patients with chronic CSC were intravitreally injected with 1.25 mg/0.05 ml of bevacizumab. The need for retreatment was evaluated if spectral-domain optical coherence tomography showed the presence of subretinal fluid at the time of a 1-month follow-up examination. Best-corrected visual acuity and central foveal thickness were compared between baseline and 1 year after the first injection. Results: The mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity improved from 0.23 +/- 0.46 to 0.17 +/- 0.47 and the mean central foveal thickness significantly decreased from 323 +/- 98 mu m to 171 +/- 63 mu m (p < 0.05). Conclusion: The intravitreal injection of bevacizumab is well tolerated in maintaining vision and reducing serous retinal detachment in patients with chronic CSC, as evaluated at a 1-year follow-up examination. Copyright (C) 2010 S. Karger AG, Basel